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We searched for cellular proteins that interact with Epstein–Barr (EBV) virus nuclear antigen-1, which is a latent EBV
origin-binding protein detected in all EBV latently infected cells and essential for maintenance of the latent EBV genome, by
a yeast two-hybrid screening of a B lymphocyte cDNA library in this study. Interaction of polypeptides synthesized from three
selected cDNA clones with EBNA-1 proteins was confirmed in vitro using their glutathione-S-transferase-fusion polypeptides
and by coimmunoprecipitation analyses of B cell extracts with anti-EBNA-1 monoclonal antibodies and monospecific
antibodies against cellular proteins of interest. We report the following: (i) Karyopherin a (karyopherin a1, hSRP1, and NPI-1),
an adaptor subunit of nuclear localization signal receptors, which direct proteins to the nuclear pore, interacted with EBNA-1.
(ii) EBNA-1 proteins endogenous in the B cell line Raji of Burkitt lymphoma origin bound to another adaptor protein,
karyopherin a2 (hSRP1a, hRch1), interactions of which to recombinant EBNA-1 polypeptides were previously reported. (iii)
Nearly 90% of all the cDNA clones examined was p32 (SF2-associated P32, p32/TAP, and gC1q-R), and endogenous EBNA-1
proteins in the Raji cells bound to p32, a potential of which to affect localization of EBNA-1 in transfected Vero cells has been
recently suggested. These results suggest that EBNA-1, which has the unique NLS containing Lys–Arg and overlapping with
one of the phosphorylation domains, is recognized and transported to the nuclei by these two distinct karyopherin a proteins,
which are differentially expressed in different cell types, implying a regulatory localization system for EBNA-1. © 2000 Academic
PressINTRODUCTION
Epstein–Barr virus (EBV) nuclear antigen-1 and the
recently identified BARF0 are the only two viral-encoded
proteins that are expressed in type I latency (the EBNA-
1-only program) of EBV (Kieff, 1996; Fries et al., 1997).
EBNA-1 is also expressed in a subpopulation of normal
B cells latently infected with EBV (Chen et al., 1995;
Miyashita et al., 1997), although in the resting EBV-pos-
itive normal B lymphocytes EBNA-1 mRNA from the
BamHI Q promoter, Qp, was not detected (Davenport and
Pagano, 1999). EBNA-1 plays an essential role(s) in the
maintenance/segregation of latent EBV plasmid DNA
and possibly in EBV DNA partitioning to host chromo-
somes (Aiyar et al., 1998; Lee et al., 1999). EBNA-1 trans-
activates the promoter(s) Wp/Cp for a polycistronic mes-
sage of all six EBNAs in type III latency (Rickinson and
Kieff, 1996) and negatively regulates Qp during latency I
in which none of the other EBNAs is transcribed (Kieff,
1996; Davenport and Pagano, 1999). EBNA-1 also resem-
bles “RGG” RNA binding proteins (Snudden et al., 1994).
In addition, it was reported that EBNA-1 antisense oli-
godeoxyribonucleotides inhibited proliferation of EBV-1 To whom reprint requests should be addressed. Fax: 81-3-5285-
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11immortalized cells (Roth et al., 1994), EBNA-1 expression
in transgenic mice induced lymphoma (Wilson et al.,
1996), EBNA-1 increased the tumorigenicity and meta-
static capability of a nasopharyngeal carcinoma cell line
(Sheu et al., 1996), and EBNA-1 expression was associ-
ated with enhanced expression of CD25 in a Hodgkin
cell line (Kube et al., 1999).
It is well established that EBNA-1 is localized in the
nucleus; however, whether and how a cellular mecha-
nism controls its subcellular or subnuclear localization,
which might play a role in the regulation or modulation of
its functions, are only poorly understood. EBNA-1 is
phosphorylated at serine residues (Hearing and Levine,
1985; Polvino-Bodnar et al., 1988; Frappier and O’Donnell,
1991), yet a functional role(s) of this phosphorylation
remains largely unknown. No enzymatic activity has
been associated with EBNA-1 (Frappier and O’Donnell,
1991), and EBNA-1 functions in the absence of other EBV
proteins during the latency of type I and probably types
II and III. Therefore identification and characterization of
cellular proteins that interact with EBNA-1 protein are
crucial to elucidate the molecular mechanisms of EBNA-
1’s regulatory function(s). It has been suggested that
EBNA-1 proteins bind to p32 [also known as SF2-asso-
ciated p32, p32/TAP (HIV Tat-associated protein), and
gC1q-R] (Wang et al., 1997; Chen et al., 1998), which is
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cellular coactivator that bridges EBNA-1 to TFIIB (Wang
et al., 1997; Yu et al., 1995). Recently, it has also been
reported that EBNA-1 binds to human RPA (hSSB), the
replicative single-strand DNA binding protein that inter-
acts with a variety of cellular and viral proteins (Zhang et
al., 1998), and to EBP2 (EBNA-1 binding protein 2) (Shire
et al., 1999).
In the present study, we have searched for cellular
proteins that bind to EBNA-1 using an interaction trap/
two-hybrid method (Chien et al., 1991) of a human B
lymphocyte cDNA library. Interactions of the two-hybrid
selected cDNA proteins with EBNA-1 were directly ana-
lyzed using the glutathione-S-transferase–cDNA clone
fusion polypeptides and specific antibodies against pro-
teins of interest. Furthermore we analyzed coimmuno-
precipitation of the cellular proteins using anti-EBNA-1
monoclonal antibodies.
In this report, we show that EBNA-1 interacts with
karyopherin a protein [also known as karyopherin a1/
SRP1/NPI-1 (Mattaj and Englmeier, 1998)], referred to
s NPI-1 hereafter, implying that the nuclear transport of
BNA-1 is mediated by this adaptor subunit of the nu-
lear import receptor. The karyopherin a adaptor pro-
teins heterodimerize with karyopherin b/importin b pro-
eins through the 41-aa importin-b-binding (IBB) domain,
forming nuclear import receptors. The nuclear import
receptors transport karyophilic proteins to the nucleus
via the nuclear pore complex and release them upon
association with RanGTP. We show also that endoge-
nous EBNA-1 proteins in B cells interact with another
adaptor subunit called karyopherin a2 [known also as
hSRP1a/NPI-3/hRch1 (Mattaj and Englmeier, 1998)], re-
erred to as Rch1 here. The significance of EBNA-1 in-
eraction with these two discrete karyopherin as is dis-
cussed.
RESULTS
Search for EBNA-1-interacting cellular proteins
by interaction trap system and in vitro binding
of EBNA-1 proteins to GST-fusion polypeptides
of cellular cDNA clones
For a yeast two-hybrid system (Chien et al., 1991) to
screen cellular proteins that interact with EBNA-1 pro-
teins, we constructed a truncated form of bait using the
EBNA-1 deletion mutant recombinant DNA, p205, which
has a deletion of 700 6 20 bp from the Gly-Gly-Ala repeat
region of 717 bp in the B-95 strain (Yates et al., 1985). The
Gly–Gly–Ala repeat domain inhibits the antigen process-
ing and MHC class-I-restricted presentation via the ubiq-
uitin/proteasome-dependent protein degradation of
EBNA-1 (Levitskaya et al., 1995, 1997), but the repeat
domain is dispensable for the other functions of EBNA-1.
The triplet repeat domain-deleted form of EBNA-1 was
more efficient as two-hybrid bait than the aa 451–641segment of EBNA-1 initially used in this study. We ob-
tained 36 yeast colonies, which were dependent on
EBNA-1 synthesized in the yeast cells in both assays of
b-galactosidase and HIS3 expression. From these two-
hybrid screening positive yeast colonies, cDNA clones
were extracted and subcloned. We analyzed base se-
quences of the 36-cell cDNA clones and carried out a
computer-aided homology search of the base sequences
using BLASTN 1.4.11 (to be published elsewhere). To test
whether polypeptides synthesized from the cDNAs of
interest bind to EBNA-1 in vitro, glutathione-S-trans-
ferase fusion polypeptides were constructed (Fig. 1B)
and transfected to Escherichia coli BL21 strain for ex-
pression. The retention of EBNA-1 proteins from cell
lysates of Raji, the EBV latency type III cell line of Burkitt
lymphoma origin, by the GST-fusion proteins that had
been bound on glutathione–Sepharose 4B beads, was
examined.
One interaction-trap-positive cDNA was NPI-1, and its
GST-fusion bound to EBNA-1 in the presence and
absence of B cell lysates
The 502-base sequence of the cDNA 3–90 was in
agreement with the 424- to 925-bp region of hSRP1
[GenBank, Accession No. S75295; identities 5 498/
502 (99%)]. In addition, the reactivity of the GST-fusion
protein of the cDNA clone 3-90 (Fig. 1B), referred to as
GST-3-90 hereafter, to NPI-1-specific antibodies was
confirmed by Western blot analysis (Fig. 2, lanes 7 and
8). These results indicate that the cDNA 3-90 is a
cDNA of NPI-1. The protein retention assay of proteins
in Raji cell lysate by GST-3-90 polypeptides on the
glutathione beads demonstrated that the GST-3-90
polypeptides bound to EBNA-1 proteins in the Raji
cells (Fig. 2, lane 5).
We next addressed the question of whether the inter-
action of the GST-3-90 and EBNA-1 proteins was medi-
ated by other proteins in the Raji cell lysates. The
EBNA-1 mutant EBNA-1(DGA), which is deficient in the
Gly-Gly-Ala repeat region (Fig. 1A), is exactly the same
truncated form as that employed in the two-hybrid
screening bait in this study. The expressed EBNA-1(DGA)
polypeptide was 58 kDa as determined from immunoblot
analysis, larger than its predicted size, as in the case of
the full-size EBNA-1 protein with apparent and predicted
sizes of 78 and 56 kDa, respectively (Polvino-Bodnar et
al., 1988). The EBNA-1(DGA) polypeptides were incu-
bated with the glutathione-Sepharose 4B bead-attached
GST-3-90 fusion proteins. All proteins trapped by GST-
3-90 polypeptides were eluted by adding the reduced
form of glutathione and analyzed by Western blotting. A
faint but clear 58-kDa band corresponding to the EBNA-
1(DGA) and a smaller broadband, probably its proteolytic
product, were detected (Fig. 2, lane 9), indicating that the
NPI-1 polypeptides were capable of interacting with the
rid scr
112 ITO ET AL.EBNA-1(DGA) proteins in the absence of B cell lysates.
However, it should be noted that the binding of the
FIG. 1. Structure of EBNA-1 and construction of EBNA-1(DGA) and gl
clones. The Gly–Gly–Ala repeat region is shown as a hatched box with
functional domains of EBNA-1 are delineated by solid bars underneat
indicated in each (A) (1) Ambinder et al. (1991); (2) Polvino-Bodnar
Polvino-Bodnar and Schaffer (1992); (4) Wang, Y. et al. (1997); (5) Shire
et al. (1995); (9) Inoue et al. (1991), Chen et al. (1993); (10) Polvino-Bodna
EBNA-1(DGA) was constructed by inserting the PCR-amplified p205
Gly–Gly–Ala repeats of 717 bp (Yates et al., 1985), into the expressi
GST-fusion polypeptides, GST-3-90, GST-3-46, and GST-3-8, which we
shown in (B). These cDNA clones were selected by the yeast two-hybEBNA-1(DGA) proteins to the NPI-1 polypeptides was
considerably weaker than the EBNA-1 proteins from theRaji cells; this less stable interaction might be due to the
absence of B cell proteins and/or might be because of
ne-S-transferase-fusion polypeptides of interaction trap-positive cDNA
open bar representing the EBNA-1 gene of 641 aa at the top, and the
he diagram was drawn based on the following references which are
(1988); (3) Hearing and Levine (1985), Polvino-Bodnar et al. (1988),
1999); (6) Marechal et al. (1999); (7) Snudden et al. (1994); (8) Mackey
1988), Yates and Camiolo (1988); and (11) Levitskaya et al. (1995, 1997).
sequence, which carries a 700 6 20-bp deletion at the site of the
tor pRSETB on the bottom (A). The schematic representation of the
tructed from three cDNA clones, 3-90, 3-46, and 3-8, respectively, is
eening of the human B cell cDNA library (B).utathio
in the
h (A). T
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re consplausible less or different phosphorylation of EBNA-
1(DGA), as discussed later.
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113EBNA-1 AND NPI-1, ADAPTOR OF NUCLEAR TRANSPORT RECEPTORAnother cDNA clone was Rch1, and its GST-fusion
polypeptides interacted with endogenous EBNA-1
proteins in B cells
The base sequence of another cDNA clone prepared
from a yeast two-hybrid positive colony, the cDNA clone
3-46, was identical to the 566- to 1230-bp region of
another member of the karyopherin a family,
Rch1(hSRP1a) [GenBank Accession No. U28386; identi-
ies 5 659/665 (99%)]. In support of these sequence data,
he GST-fusion polypeptides containing another cDNA
lone 3-46, referred to as GST-3-46 fusion (Fig. 1B),
ositively reacted with anti-Rch1 rabbit antibodies as
hown in Fig. 3A, lane 5. The protein interaction assay on
he glutathione beads demonstrated that the GST-3-46
olypeptides bound to the Raji EBNA-1 proteins as
hown in Fig. 3A, lanes 3 and 4. The interaction of Rch1
ith EBNA-1 was reported earlier from the two laborato-
ies; Fischer et al. (1997) examined the association upon
oriP of the two proteins, testing a direct role of Rch1 on
the EBV DNA replication, and Kim et al. (1997) revealed
that EBNA-1 impeded formation of large protein com-
plexes of Rch1 with cellular proteins. In their in vitro
interaction tests, however, HA-tagged EBNA-1 polypep-
FIG. 2. In vitro binding of GST-fusion proteins of cDNA clone 3-90 to
EBNA-1 in Raji cell lysates. GST-3-90-fusion proteins bound to gluta-
thione-Sepharose 4B beads were incubated with EBNA-1 proteins in B
cell lysates. Lane 1, EBNA-1 proteins in Raji cell lysates detected with
anti-EBNA-1 monoclonal antibody EN2002; lane 2, reaction of DG75
cell lysates with the monoclonal antibody EN2002 as negative control;
lane 3, GST proteins as negative control were bound to glutathione-
Sepharose 4B, incubated with Raji cell lysates, eluted by adding glu-
tathione, and assayed by Western blotting with the antibody EN2002;
lane 4, GST proteins bound to glutathione-Sepharose 4B were incu-
bated with cell lysates of EBV-negative B cell line DG75, eluted with
glutathione, applied to Western blotting using the antibody EN2002;
lane 5, GST-3-90 fusion proteins were bound to glutathione-Sepharose
4B, incubated with Raji cell lysate, eluted with glutathione and analyzed
by immunoblotting with the antibody EN2002; lane 6, GST-3-90-fusion
proteins were incubated with DG75 cell lysate, then assayed as de-
scribed for lane 5; lane 7, GST-3-90 fusion proteins bound on glutathi-
one-Sepharose 4B were incubated with Raji cell lysate, eluted, assayed
by immunoblotting with the anti-NPI-1 rabbit antibody; lane 8, GST-3-90
fusion proteins bound on glutathione-Sepharose 4B were incubated
with DG75 cell lysate, followed by the assay as noted for lane 7. Lane
9, EBNA-1(DGA) polypeptides synthesized in E. coli were incubated
with glutathione-Sepharose 4B bead-bound GST-3-90 fusion proteins,
eluted with glutathione, and applied to immunoblotting with the EN2002
antibody.tides, which were translated in vitro, or HeLa S3 cells
(Kim et al., 1997), an epitheloid cell line established fromcervical carcinoma and carries subgenomic fragments of
human papilloma virus type 18 DNA (Meissner 1999),
and recombinant EBNA-1 polypeptides synthesized in
insect cells (Fischer et al., 1997) were examined. Our
esults have demonstrated the interaction of Rch1 with
BNA-1 proteins endogenous in the Raji B cell line by the
irect biochemical affinity assay in conjunction with
estern blot analysis (Fig. 3A). The discrepancy between
ur results and the far-Western blot analysis, in which
ch1 did not interact with EBNA-1 proteins from B cells
Fisher et al., 1997), seems to be due to a higher detect-
ability by the GST-affinity analysis of a low concentration
of proteins.
FIG. 3. Binding of GST-fusion proteins of cDNA clones 3-46 and 3-8
to EBNA-1 proteins in Raji cell lysates. (A) GST-3-46. Lane 1, detection
with the anti-EBNA-1 monoclonal antibody EN2002 of EBNA-1 in Raji
cell lysate; lane 2, Raji cell lysates were incubated with GST proteins as
negative control that were bound on glutathione-Sepharose 4B beads
beforehand, eluted with glutathione, and analyzed by Western blotting
with the monoclonal antibody EN2002; lanes 3 and 4, Raji cell lysates
were incubated with GST-3-46 polypeptides, which were bound on
glutathione-Sepharose 4B beads, eluted, and analyzed by immunoblot-
ting using EN2002. Two independently constructed GST-3-46 fusion
polypeptides were separately analyzed in lanes 3 and 4; lane 5, GST-
3-46 polypeptides were incubated with glutathione-Sepharose 4B,
eluted, and detected by immunoblotting using the anti-Rch1 rabbit
antibodies. (B) GST-3-8. Lane 1, direct detection of EBNA-1 proteins in
Raji cell lysates as positive control with the anti-EBNA-1 monoclonal
antibody EN2002; lane 2, Raji cell lysates were incubated with gluta-
thione-Sepharose 4B bead-bound GST proteins as negative control,
eluted with glutathione from the beads, and analyzed by Western
blotting with the antibody EN2002. Lanes 3 and 4, Raji cell lysates were
incubated with GST-3-8 fusion polypeptides that were bound to gluta-
thione-Sepharose 4B beads, eluted from the beads, and analyzed by
Western blotting with EN2002. Twofold cell lysates were added in the
incubation mixture that was applied on lane 4 than that on lane 3; lane
5, GST-3-8 polypeptides were incubated with glutathione-Sepharose
4B, eluted with glutathione, and detected by immunoblotting using the
mouse anti-p32/(gC/q-R) antibody.
114 ITO ET AL.The other cDNA clone was p32 and its GST fusion
interacted with B cell endogenous EBNA-1
The base and deduced amino acid sequence of clone
3-8 agreed with that of 359–903 nucleotides (identity
88%) and 94–275 amino acids (identity 100%) of gC1q-R
(EMBL X75913), that of 269–813 nucleotides (identity
88%) and 90–271 amino acids (identity 100%) of SF2p32
(GenBank M69039), and that of 91–272 amino acids
(identity 100%) of TAP (Tat-associated protein) (Yu et al.,
1995). This cellular protein, which is known by various
names, is referred to as p32 hereafter. It turned out that
sequences of 32 of all 36 cDNA clones obtained using
the Gly–Gly–Ala repeat-deleted bait conformed with p32.
Further confirmation that the cDNA 3-8 is a p32 clone
was obtained from the positive reaction of the GST-
fusion polypeptides of clone 3-8, referred to as GST-3-8,
(Fig. 1B), to the anti-p32 (gC1q-R) mouse antibody 60.11
(Fig. 3B, lane 5). The retention assay of the GST-3-8
polypeptides in a similar fashion indicated an interaction
with the Raji endogenous EBNA-1 proteins, too (Fig. 3B,
lanes 3 and 4). The region of p32 in the GST-3-8 is shorter
than the mature form of p32 (aa 74–282) (Honore et al.,
1993), indicating that the amino-terminal 16 aa (aa 74–89,
SF2p32 sequence) and carboxyl end 11 aa (aa 272–282,
SF2p32) are not required for the interactions with
EBNA-1 proteins. Furthermore these results have con-
firmed that EBNA-1 proteins endogenous in Raji cells
bind in vitro to p32 proteins, whose coimmunoprecipita-
tion with recombinant EBNA-1 proteins synthesized in
the simian Cos-1 and human 293 cells, which were
established by transformation of kidney cells with SV40
and adenovirus type 5, respectively, were previously re-
ported (Chen et al., 1998; Wang et al., 1997).
Coimmunoprecipitation of EBNA-1 and NPI-1 proteins
endogenous in B cells
To determine whether EBNA-1 interacts with endoge-
nous NPI-1 in B lymphocytes, coimmunoprecipitation as-
say was employed using the Raji cell lysates. Proteins
were coprecipitated with the anti-EBNA-1 monoclonal
antibody EN2002 and examined by Western blot analysis
with the rabbit anti-NPI-1 antibodies. A very broad band
or doublet of 50–60 kDa in agreement with the NPI-1
double bands (Kohler et al., 1997; Nadler et al., 1997) was
detected (Fig. 4, lane 1), indicating EBNA-1 binding to
this NLS adapter protein in vivo. EBNA-1 proteins were
detected using the two different anti-EBNA-1 mouse
monoclonal antibodies, EN2002 and OT1x (Fig. 4, lanes 2
and 3). In the analyses of the cell lysate immunoprecipi-
tates from the cell lysates by the anti-NPI-1 antibodies
provided by Dr. P. Palese, two faint bands were detected
with the anti-EBNA-1 EN2002 monoclonal antibodies:
one at 66 kDa corresponding to the full-size EBNA-1 and
another at 45 kDa, possibly its proteolytic product (data
not shown). This low recovery of EBNA-1 with the anti-NPI-1 antibodies is considered to be due to their lower
reactivity to the protein complexes or destabilization of
the EBNA-1–NPI-1 complexes by the antibodies.
We also performed confocal microscopy analyses of
Raji cells using the anti-NPI-1 antibodies obtained from
Dr. P. Palese and from Dr. Y. Yoneda, the anti-EBNA-1
monoclonal antibody OT1x and the anti-EBNA-1 rat
monoclonal antibody 2B4-1. NPI-1 proteins were stained
in the cytoplasm of all the examined cells and in the
nuclei of ,10% in number. However, it was difficult to
assess colocalization of EBNA-1 and NPI-1 proteins in
the cells due to the too low immunofluorescent staining
of EBNA-1 because of the antibodies’ insufficient affinity
to antigens fixed for immunofluorescence analysis (not
shown).
DISCUSSION
EBNA-1 is the sole viral protein essential for the re-
tention of EBV plasmid DNAs, which replicate once per
cell cycle and are maintained at stable copy numbers per
cell (Kieff, 1996; Rickinson and Kieff, 1996). Recently, it
was demonstrated that EBNA-1 is not indispensable in
the long-assumed replication of plasmids with oriP but is
required for prevention of the rapid elimination of de
novo synthesized oriP plasmids (Aiyar et al., 1998). More-
over EBNA-1 is considered to mediate EBV plasmid par-
titioning to cell chromosomes (Marechal et al., 1999).
EBNA-1 is needed for efficient and stable latent EBV
infection of B cells (Lee et al., 1999), and the latent origin
of replication of EBV is consistent with a stochastic
model for DNA synthesis initiation (Kirchmaier and Sug-
den, 1998). EBNA-1 homodimers bind directly and spe-
cifically to the two sites: the family of repeats (FR) and the
dyad symmetry element (DS) in oriP (Inoue et al., 1991;
FIG. 4. Coimmunoprecipitation of endogenous NPI-1 and EBNA-1
proteins from Raji cell lysates with the anti-EBNA-1 monoclonal anti-
bodies. Lane 1: Raji cell lysates were incubated with the anti-EBNA-1
monoclonal antibody EN2002 at 4°C for 1 h, protein G beads were
added, and mixed gently at 4°C overnight, and the antigen–antibody
complexes were eluted from protein G beads. The eluted proteins were
analyzed by Western blotting using rabbit anti-NPI-1 antibody; lane 2:
Raji cell EBNA-1 proteins were detected with the anti-EBNA-1 mono-
clonal antibody EN2002, lane 3, Raji cell EBNA-1 proteins were de-
tected with the anti-EBNA-1 monoclonal antibody OT1x.Chen et al., 1993; Kieff, 1996), linking the EBV DNA
(Mackey et al., 1995) and Qp (Sung et al., 1994). EBNA-1
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115EBNA-1 AND NPI-1, ADAPTOR OF NUCLEAR TRANSPORT RECEPTORhas been considered to play its roles through interaction
with a cellular protein(s).
Cellular proteins that interact with EBNA-1
We suspect the activity(ies) and its subcellular/sub-
nuclear localization of this multifunctional nuclear pro-
tein, whose mRNA expression is regulated by a cell cycle
with no detectable change in protein levels during la-
tency 1 (Davenport and Pagano, 1999), might be modu-
lated by cellular proteins. These working hypotheses led
us to search for cellular proteins which interact with
EBNA-1 proteins employing a yeast two-hybrid system.
In the present study, we have demonstrated the inter-
action of EBNA-1 with NPI-1 protein. In addition this
study exhibited that endogenous EBNA-1 proteins in the
Raji B cell line of BL origin and latency type III bound to
Rch1, whose interactions with baculovirus-expressed re-
combinant or hemagglutinin-tagged EBNA-1 polypep-
tides using different types of cells were reported earlier
(Fisher et al., 1997; Kim et al., 1997). Our results con-
irmed that EBNA-1 endogenous in Raji cells interacted
ith p32, whose coimmunoprecipitation with recombi-
ant EBNA-1 polypeptides in the cell lines of a different
ell type established by viral transformation and whose
olocalization with tagged EBNA-1 in Vero cells were
reviously reported (Chen et al., 1997; Wang, Y. et al.,
997).
ignificance of interactions of EBNA-1 with NPI-1
nd Rch1
What does the interaction of EBNA-1 with these two
iscrete NLS adapter proteins, NPI-1 and Rch1, suggest?
irst, EBNA-1 protein intriguingly interacts with these two
LS adaptors, which share 44.8% amino acid sequence
omology (Weis et al., 1995), implying its trafficking to the
ucleus mediated by both of these proteins. This might
uggest not only conceivable redundancy of a gene or
rotein of an essential function such as the nuclear
ransport but also regulation of the import system. In
ontrast to EBNA-1, nuclear import of Stat1 was mediated
y NPI-1, not by Rch1 (Sekimoto et al., 1997). DNA heli-
ase Q1/RecQL interacted with Rch1 and Qip1, the third
uman karyopherin a, but not with NPI-1 (Seki et al.,
997). These results suggest differential interactions of
he NLS adapters/receptors to different karyophilic pro-
eins. Interestingly, at least two more karyopherin a’s
have been shown to be expressed in human tissues
(Kohler et al., 1997; Malik et al., 1997; Takeda et al., 1997;
achury et al., 1998). On the other hand, influenza A virus
ucleoprotein, NP, has the two overlapping nonconven-
ional NLSs, SxGTKRSYxxM for binding to NPI-1 and
KRSxxxM for binding to Rch1 (Wang et al., 1997). Inter-
stingly, in the presence of HeLa cell cytosol, Rch1
ound to SV40T antigen, whereas NPI-1 and Qip1 bound
oorly (Miyamoto et al., 1997); in contrast, both NPI-1 and
1
tch1 strongly bound to SV40T antigen in the presence of
ysates of Raji or Jurkat cells (Nadler et al., 1997). NPI-1
inds to NLSs of Myc, HSV-1 ICP8 in the cytosolic extract
f Raji cells, but not to either of the NLSs in the extract of
urkat cells (Nadler et al., 1997). These indicate that
ecognition of the NLSs by the adaptors is dependent on
he cell type and modulated by cytosolic proteins (Nadler
t al., 1997). From this viewpoint, it is intriguing that the
nteraction of Rch1 with EBNA-1 required not only the
nique NLS of EBNA-1, KRPRSPSS at aa 379–386
Ambinder et al., 1991), but also its upstream, aa 1–90,
nd downstream, aa 327–477 (Kim et al., 1997) compo-
ents. It is also noteworthy that a sequence of lys-arg in
he NLS is shared between EBNA-1 and these proteins
ecause the critical role of the lys-arg residues for NLS
as been delineated by the X-ray crystallographic anal-
sis of a tandem array of armadillo repeats in the yeast
aryopherin a (Conti et al., 1998).
Second, multiple karyopherin a’s have recently been
uggested to be expressed in one cell type and differ-
ntially in different cell types (Kohler et al., 1997). The two
differentially expressed karyopherin a’s in leukocyte cell
ines could be induced by cell activation (Nadler et al.,
997). In contrast to Rch1, NPI-1 was at higher levels in
he Raji and Jurkat cell lines than in the HeLa and several
ther cell lines (Kohler et al., 1997). Thus EBNA-1’s nu-
lear import might be more dependent on NPI-1 in B and
lymphocytes.
Third, function or activities of EBNA-1 proteins might
e controlled through the nucleocytoplasmic trafficking
nd the localization pattern within the nucleus; diffused
nd granular localization patterns of EBNA-1 mutant pro-
eins in the nuclei were described (Polvino-Bodnar et al.,
988). Nuclear localization of EBNA-1 proteins has been
ell documented, but in a small number of EBV latently
nfected cells, EBNA-1 is detected in the cytoplasm,
hich usually is regarded as nuclear leakage during the
xperimental process (Petti et al., 1990). It is intriguing
hat Wang et al. (1997) reported that full-length cytoplas-
ic p32 proteins translocated nuclear EBNA-1 into the
ytoplasm. The actual function of p32, however, remains
o be carefully elucidated, because it has recently been
evealed that p32 has a new fold, giving a high negative
harge density on one side of its trimer (Jiang et al.,
999), is localized mainly in the mitochondrial matrix
Matthews et al., 1998), and interacts with a very wide
ariety of cellular and viral proteins, namely ASF/SF2
plicing factor, lamin B receptor protein (p58), gC1q-R,
FIIB, hyaluronic acid, kininogen, vitronectin, HIV rev and
at, HSV-1 ORF P, EBNA-1, and Ad2 core protein V (Bruni
nd Roizman, 1996; Wang et al., 1997; Chen et al., 1998;
atthews and Russell, 1998). It, however, seems note-
orthy that p32 is considered to be involved in nucleus–
itochondrion interactions (Matthews and Russell,998). On the other hand, it has recently been reported
hat accumulation rate and concentration of SV40 T an-
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116 ITO ET AL.tigen in the nucleus were regulated by phosphorylation
in the vicinity of the NLS (Jans, 1995). EBNA-1 is phos-
phorylated at the cluster of serines at aa 380–397
(Polvino-Bodnar et al., 1988) that overlaps with its NLS
defined by Ambinder et al. (1991), as we indicate in Fig.
1A by combining the data in the three papers (Hearing
and Levine, 1985; Polvino-Bodnar et al., 1988; Polvino-
Bodnar and Schaffer, 1992). In addition, it is noteworthy
that the aa 380–397 region has the serine-rich QSSSGSP
stretch that immediately follows the NLS. Moreover, Kim
et al. (1997) have indicated that the amino-terminal and
central domains encompassing the EBNA-1 NLS contrib-
ute to its stable interaction with Rch1. In fact, the binding
of EBNA-1(DGA) synthesized in E. coli to NPI-1 was
weaker in comparison to Raji EBNA-1 (Fig. 2), although it
might be explained as by the absence of other cellular
proteins as described above. Thus the nuclear trafficking
of EBNA-1 proteins might be controlled by its phosphor-
ylation.
Finally, Rch1 (Rag cohort) is the protein initially defined
as a major cell factor that interacted with the V(D)J
recombinase-activating gene RAG-1, expression of which
was restricted to immature lymphoid cells (Cuomo et al.,
1994). On the one hand, the human homolog of the yeast
SRP1 that interacted with RAG-1 (Cortes et al., 1994) is
identical to the NPI-1 identified as a cellular protein that
interacted with NP of influenza A virus (O’Neill and
Palese, 1995); we have confirmed their perfect homology
using the sequences in the former report (Cortes et al.,
1994) and the latter one, i.e., GenBank S75295 (O’Neill
and Palese, 1995). On the other hand, EBNA-1 induced
expression of RAG-1 and RAG-2 (Srinivas and Sixbey,
1995). Taken together, the transport of RAG-1 and its
inducer EBNA-1, both mediated by the same pair of
karyopherin a proteins, might efficiently enhance V(D)J
ecombinase activity; this could result in chromosome
ranslocation, eliciting cytogenetic alterations associated
ith EBV infection such as c-myc protooncogene trans-
ocation into an immunoglobulin locus (Haluska et al.,
986).
erspectives
It is consistent with the recently clarified function of
BNA-1 for the retention, not for the synthesis, of EBV
NA (Aiyar et al., 1998; Lee et al., 1999; Shire et al., 1999)
hat no known cellular protein directly involved in DNA
uplication has been detected as an EBNA-1 binding
actor by our protein interaction-trap system with either
f the two different baits used in our study. The dual
ecognition of the unique NLS of EBNA-1 and its pre-
icted nuclear transport by NPI-1 and Rch1, which might
e differentially controlled by phosphorylation and cellu-
ar factors, is considered to facilitate possible modula-
ion of subcellular localization and activities of the mul-
ifunctional EBNA-1 proteins.MATERIALS AND METHODS
ntibodies
Mouse monoclonal antibody EN2002 against the trun-
ated EBNA-1 polypeptide aa 451–641 was generated
arlier in our laboratories (to be published elsewhere).
nti-EBNA-1 mouse monoclonal antibody OT1x (Chen et
l., 1993) and rat monoclonal antibody 2B4–1 (Grasser et
l., 1994) were kindly provided by Dr. Y. Middeldorp
Organon Teknika, The Netherlands) and Dr. F. A.
rasser (Universitatskliniken, Homburg, Germany) re-
pectively. The anti-gC1q-R (p32) monoclonal antibody
0.11 was a kind gift from Dr. B. Ghebrehiwet (State
niversity of New York at Stony Brook). The anti-Rch1
abbit antibody was kindly provided by Drs. M. V. Na-
hury and K. Weis (University of California, San Fran-
isco). Two rabbit antibodies against NPI-1 were pro-
ided kindly by Dr. P. Palese (Mount Sinai School of
edicine, New York) and Dr. Y. Yoneda (Osaka University,
apan).
rotein–protein binding assay with GST-fusion
olypeptides and glutathione beads
GST-fusion polypeptides from the yeast two-hybrid se-
ected cDNA clones were bound to glutathione-Sepha-
ose 4B beads (Pharmacia, Sweden). Proteins of inter-
sts in Raji cells or DG75 cells, which were grown at
7°C in a CO2 incubator, were added to the GST-fusion
protein-bound glutathione-Sepharose 4B and mixed at
4°C. The bound proteins were eluted with glutathione,
resolved on an 8% SDS–polyacrylamide gel, and electro-
transferred to nitrocellulose membrane (Bio-Rad). The
membrane was then incubated with the antibodies indi-
cated in the text, and proteins were detected with the
alkaline phosphatase detection system (Bio-Rad).
Coimmunoprecipitation assay
Cell lysates of interest were incubated with antibodies at
4°C for 1 h. Protein G–agarose beads were added to the
reaction and mixed at 4°C, and subsequently the absorbed
immunoprecipitates were eluted from protein G.
Western blot analyses
Proteins were separated on an 8% SDS–polyacryl-
amide gel at 15 V/cm and electrotansferred to nitrocel-
lulose membrane. Subsequently, the membrane was in-
cubated with indicated primary antibodies at 37°C for 90
min, followed by the secondary alkaline phosphatase-
conjugated antibodies (Bio-Rad), and treated with the
immunoblotting detection reagent (Bio-Rad).
Cells and lysatesThe EBV-negative DG75 human B cell line established
from Burkitt’ lymphoma was a kind gift from Dr. G. Klein
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fected B cell line Raji, also BL-derived, was purchased
from ATCC (Rockville, MD). The B cells were cultured in
RPMI medium containing 10% fetal bovine serum, 100
mg/ml kanamycin, 25 mg/ml amphotericin B (Boehringer-
anheim, Germany) at 37°C in a 5% CO2 humidified
incubator. Cells were centrifuged, washed, and resus-
pended in a cell lysate preparation buffer (10 mM Tris–
HCl, pH 7.5, 25% glycerol, 2 mM Mg2Cl, 0.1 mM EDTA, 0.5
mM DTT, 50 mM NaCl, 0.1% NP-40, 0.5 mg/ml aprotinin,
0.5 mg/ml leupeptin, 0.7 mg/ml pepstatin, 20 mg/ml phos-
phoramidon). Subsequently, harvested cells were ultra-
sonicated and centrifuged, and the supernatant was
used.
Preparation of glutathione-S-transferase fusion
proteins
For construction of GST-fusion polypeptides, DNA frag-
ments from two-hybrid screening positive cDNA clones
were inserted in the polylinker segment of PGEX-5X-1
(Amersham Pharmacia Biotech). The expression vectors
were used to transform the E. coli BL21(DE3) strain. The
transformed E. coli cells were cultured, harvested after
IPTG induction, and ultrasonicated in PBS buffer contain-
ing 0.5% N-lauroylsarcosine (Nakarai Tesque, Japan), 5%
Triton X-100 (Nakarai Tesque), 0.5 mg/ml aprotinin (Boeh-
inger-Mannheim), 0.5 mg/ml leupeptin (Boehringer-
Mannheim), 0.7 mg/ml pepstatin (Boehringer-Mannheim),
20 mg/ml phosphoramidon (Boehringer-Mannheim), and
5 mM dithiothreitol on ice with a MICROSON ultrasonic
cell disruptor (Heat Systems). The disrupted cells were
then spun at 14,000 rpm at 5°C for 10 min, and the
supernatants were used. The truncated EBNA-1 polypep-
tide lacking the Gly–Gly–Ala repeats, EBNA-1(DGA), was
generated from p205 that lacks the Gly–Gly–Ala repeated
region of EBNA-1 (Fig. 1A) and was provided from Dr. B.
Sugden (Wisconsin University) (Yates et al., 1985). The
truncated EBNA-1 sequence was amplified by PCR using
the primers, 59-gccggatcccatgtctgacgaggggccag-39 and
9-gccaagcttttattctttagtgcggggga-39, cleaved with HindIII
nd BamHI, followed by insertion into the pRSETB vector
Invitrogen, The Netherlands). The expression vector pR-
ETB-EBNA-1(DGA) (Fig. 1A) was used to transform the
. coli strain BL21(DE3).
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